Search our Database of Scientific Publications and Authors

I’m looking for a

    166 results match your criteria Hypercholesterolemia Polygenic

    1 OF 4

    Abdominal aortic aneurysm-an independent disease to atherosclerosis?
    Cardiovasc Pathol 2017 Jan 29;27:71-75. Epub 2017 Jan 29.
    Department of Cardiovascular Sciences and the NIHR Leicester Cardiovascular Biomedical Research Unit, University of Leicester, Leicester, UK.
    Atherosclerosis and abdominal aortic aneurysms (AAAs) are multifactorial and polygenic diseases with known environmental and genetic risk factors that contribute toward disease development. Atherosclerosis represents an important independent risk factor for AAA, as people with AAA often have atherosclerosis. Studies have shown that comorbidity is usually between ~25% and 55%, but it is still not fully known whether this association is causal or a result of common shared risk profiles. Read More

    Analysis of Children and Adolescents with Familial Hypercholesterolemia.
    J Pediatr 2017 Feb 1. Epub 2017 Feb 1.
    Department of Internal Medicine and Allied Sciences, Sapienza University of Rome, Rome, Italy. Electronic address:
    Objective: To evaluate the effectiveness of criteria based on child-parent assessment in predicting familial hypercholesterolemia (FH)-causative mutations in unselected children with hypercholesterolemia.

    Study Design: LDLR, APOB, and PCSK9 genes were sequenced in 78 children and adolescents (mean age 8.4 ± 3. Read More

    Molecular genetics of familial hypercholesterolemia in Israel-revisited.
    Atherosclerosis 2016 Dec 18;257:55-63. Epub 2016 Dec 18.
    Center for Research Prevention and Treatment of Atherosclerosis, Department of Medicine, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
    Background And Aims: Familial hypercholesterolemia (FH) is an autosomal dominant disease caused by mutations in the genes for LDL receptor (LDLR), apolipoprotein B (APOB) and proprotein convertase subtilisin/kexin type9 (PCSK9). The purpose of the current investigation was to define the current spectrum of mutations causing FH in Israel.

    Methods: New families were collected through the MEDPED (Make Early Diagnosis Prevent Early Death) FH program. Read More

    Atypical Presentation and Treatment Response in a Child with Familial Hypercholesterolemia Having a Novel LDLR Mutation.
    JIMD Rep 2016 Dec 9. Epub 2016 Dec 9.
    Robarts Research Institute and Department of Medicine, Schulich School of Medicine, Western University, London, ON, Canada, N6A 5B7.
    Familial hypercholesterolemia (FH) is an autosomal codominantly inherited disease. The severity of clinical presentation depends on the zygosity of the mutations in the LDLR, APOB, or PCSK9 genes. The homozygous form (HoFH) is associated with high mortality rate by third decade of life, while individuals with HeFH begin to suffer from premature cardiovascular disease in fourth or fifth decade of life. Read More

    Lipid phenotype and heritage pattern in families with genetic hypercholesterolemia not related to LDLR, APOB, PCSK9, or APOE.
    J Clin Lipidol 2016 Nov - Dec;10(6):1397-1405.e2. Epub 2016 Sep 22.
    Departamento de Anatomía, Embriología y Genetica Animal, Universidad de Zaragoza, Zaragoza, Spain.
    Background: A substantial proportion of individuals clinically diagnosed as familial hypercholesterolemia (FH) do not carry pathogenic mutations in candidate genes. Whether in them the high cholesterol trait is transmitted monogenically has not been studied.

    Objectives: We assessed the inheritance pattern, penetrance, and expression of high low-density lipoprotein (LDL)-cholesterol (LDLc) in families with genetic hypercholesterolemia (GH) without known causative mutations (non-FH-GH). Read More

    Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically.
    Arterioscler Thromb Vasc Biol 2016 Dec 20;36(12):2439-2445. Epub 2016 Oct 20.
    From the Robarts Research Institute (J.W., J.S.D., M.R.B., J.F.R., A.D.M., A.A.D., H.C., M.W.H., R.A.H.), Department of Biochemistry (J.S.D., M.A., A.A.D., M.W.H., R.A.H.), and Department of Medicine (P.J.Z., M.W.H., R.A.H.), Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada; Faculté de Médicine, Université de Montréal, Québec, Canada (M.-P.D., G.L., J.-C.T.); and Montréal Heart institute, Québec, Canada (D.R., C.L.-K., M.-P.D., G.L., J.-C.T.).
    Objective: Next-generation sequencing technology is transforming our understanding of heterozygous familial hypercholesterolemia, including revision of prevalence estimates and attribution of polygenic effects. Here, we examined the contributions of monogenic and polygenic factors in patients with severe hypercholesterolemia referred to a specialty clinic.

    Approach And Results: We applied targeted next-generation sequencing with custom annotation, coupled with evaluation of large-scale copy number variation and polygenic scores for raised low-density lipoprotein cholesterol in a cohort of 313 individuals with severe hypercholesterolemia, defined as low-density lipoprotein cholesterol >5. Read More

    Targeting microsomal triglyceride transfer protein and lipoprotein assembly to treat homozygous familial hypercholesterolemia.
    Crit Rev Clin Lab Sci 2017 Jan 1;54(1):26-48. Epub 2016 Oct 1.
    b Department of Cell Biology , State University of New York Downstate Medical Center , Brooklyn , NY , USA.
    Homozygous familial hypercholesterolemia (HoFH) is a polygenic disease arising from defects in the clearance of plasma low-density lipoprotein (LDL), which results in extremely elevated plasma LDL cholesterol (LDL-C) and increased risk of atherosclerosis, coronary heart disease, and premature death. Conventional lipid-lowering therapies, such as statins and ezetimibe, are ineffective at lowering plasma cholesterol to safe levels in these patients. Other therapeutic options, such as LDL apheresis and liver transplantation, are inconvenient, costly, and not readily available. Read More

    Progress in the care of familial hypercholesterolaemia: 2016.
    Med J Aust 2016 Sep;205(5):232-6
    University of Western Australia, Perth, WA.
    Familial hypercholesterolaemia (FH) is the most common autosomal dominant condition, with a prevalence of between one in 200 and one in 350 people in the general population. Untreated FH is associated with premature atherosclerotic cardiovascular disease (CVD). The prevalence of homozygous or compound heterozygous FH is now considered to be about one in 300 000 people. Read More

    Children with hypercholesterolemia of unknown cause: Value of genetic risk scores.
    J Clin Lipidol 2016 Jul-Aug;10(4):851-9. Epub 2016 Mar 21.
    Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
    Background: Familial hypercholesterolemia (FH) is caused by mutations in LDLR, APOB, or PCSK9, and in a previous study, we identified a causative mutation in these FH genes in 95% (255 of 269) of children with the FH phenotype. It has been hypothesized that a polygenic form of hypercholesterolemia is present in FH patients in whom no mutation is identified in the 3 FH genes.

    Objective: To address whether a polygenic form of hypercholesterolemia, defined as high-weighted effect of low-density lipoprotein cholesterol (LDL-C) raising SNPs expressed as the genetic risk score (GRS), is present in the remaining 14 children. Read More

    Cardiovascular risk stratification in familial hypercholesterolaemia.
    Heart 2016 Jul 28;102(13):1003-8. Epub 2016 Apr 28.
    Department of Clinical Biochemistry, Royal Free Hospital, London, UK.
    Familial hypercholesterolaemia (FH) is a common autosomal-dominant disorder in most European countries. Patients with FH are characterised by a raised level of low-density lipoprotein cholesterol and a high risk of premature coronary heart disease (CHD). Currently there is no consensus regarding the clinical utility to predict future coronary events or testing for the presence of subclinical atherosclerotic disease in asymptomatic patients with FH. Read More

    The genetic spectrum of familial hypercholesterolemia in south-eastern Poland.
    Metabolism 2016 Mar 10;65(3):48-53. Epub 2015 Nov 10.
    Centre for Cardiovascular Genetics, Institute of Cardiovascular Sciences, University College London, London, UK. Electronic address:
    Background: Familial hypercholesterolemia (FH) is a common autosomal dominant disorder with a frequency of 1 in 200 to 500 in most European populations. Mutations in LDLR, APOB and PCSK9 genes are known to cause FH. In this study, we analyzed the genetic spectrum of the disease in the understudied Polish population. Read More

    A forest-based feature screening approach for large-scale genome data with complex structures.
    BMC Genet 2015 Dec 23;16:148. Epub 2015 Dec 23.
    Department of Mathematics and Statistics, Utah State University, 3900 Old Main, Logan, 84322, UT, USA.
    Background: Genome-wide association studies (GWAS) interrogate large-scale whole genome to characterize the complex genetic architecture for biomedical traits. When the number of SNPs dramatically increases to half million but the sample size is still limited to thousands, the traditional p-value based statistical approaches suffer from unprecedented limitations. Feature screening has proved to be an effective and powerful approach to handle ultrahigh dimensional data statistically, yet it has not received much attention in GWAS. Read More

    Comparison of the effects of low-dose rosuvastatin on plasma levels of cholesterol and oxidized low-density lipoprotein in 3 ultracentrifugally separated low-density lipoprotein subfractions.
    J Clin Lipidol 2015 Nov-Dec;9(6):751-7. Epub 2015 Aug 7.
    Department of Emergency and Critical Care Medicine, School of Medicine, Keio University, Tokyo, Japan.
    Background: Plasma-oxidized (ox) low-density lipoprotein (LDL) is an atherogenic lipoprotein. The distribution of ox-LDL in plasma LDL subfractions and the effect of statins on this distribution have not been investigated in detail.

    Objective: We examined the distribution of cholesterol and ox-LDL in 3 ultracentrifugally separated plasma LDL subfractions and investigated the effects of a statin, rosuvastatin, on the levels of these lipoproteins. Read More

    Testing the Short-Term Efficacy of a Lipid-Lowering Nutraceutical in the Setting of Clinical Practice: A Multicenter Study.
    J Med Food 2015 Nov 14;18(11):1270-3. Epub 2015 Aug 14.
    4 Internal Medicine and Medical Specialties Biomedical Department, University of Palermo , Palermo, Italy .
    The main guidelines for cardiovascular disease prevention suggest that nutraceuticals could be an efficacious tool to improve lipid pattern. Our aim was to carry out a clinical trial comparing the metabolic effects of a combined nutraceutical containing both red yeast rice and polyunsaturated fatty acids (PUFAs) and a phytosterol-based approach in a setting of clinical practice. This was a multicenter open study with parallel control. Read More

    Evaluation of polygenic cause in Korean patients with familial hypercholesterolemia - A study supported by Korean Society of Lipidology and Atherosclerosis.
    Atherosclerosis 2015 Sep 30;242(1):8-12. Epub 2015 Jun 30.
    Department of Oral Biology, College of Dentistry, Yonsei University, Seoul, South Korea. Electronic address:
    Background/objective: Familial hypercholesterolemia (FH) is an autosomal dominant disorder caused by mutations in LDLR, APOB, or PCSK9. Polygenicity is a plausible cause in mutation-negative FH patients based on LDL cholesterol (LDL-C)-associated single nucleotide polymorphisms (SNPs) identified by the Global Lipids Genetics Consortium (GLGC). However, there are limited data regarding the polygenic cause of FH in Asians. Read More

    Changes in ultracentrifugally separated plasma lipoprotein subfractions in patients with polygenic hypercholesterolemia, familial combined hyperlipoproteinemia, and familial hypercholesterolemia after treatment with atorvastatin.
    J Clin Lipidol 2015 Mar-Apr;9(2):210-6. Epub 2014 Dec 16.
    Department of Emergency Medicine, School of Medicine, Keio University, Shinjuku-ku, Tokyo, Japan.
    Background: Plasma levels of low-density lipoproteins (LDLs) are decreased through stimulation of their hepatic uptake by statins via an LDL receptor. However, it is unclear whether statins equally stimulate the hepatic uptake of all LDL subfractions.

    Objective: We compared the effects of atorvastatin on 3 LDL subfractions, and their associations with LDL-receptor activities, in Japanese patients with polygenic hypercholesterolemia (PHC), familial combined hyperlipoproteinemia (FCHL), and familial hypercholesterolemia (FH). Read More

    Improving the cost-effectiveness equation of cascade testing for familial hypercholesterolaemia.
    Curr Opin Lipidol 2015 Jun;26(3):162-8
    aPublic Health Department, Corporate Services, Hampshire County Council, Winchester, Hampshire bSolutions for Public Health, Oxford Business Park South, Cowley, Oxfordshire cCentre for Cardiovascular Genetics, Institute of Cardiovascular Science, University College London, London, UK.
    Purpose Of Review: Many international recommendations for the management of familial hypercholesterolaemia propose the use of cascade testing using the family mutation to unambiguously identify affected relatives. In the current economic climate DNA information is often regarded as too expensive. Here, we review the literature and suggest strategies to improve cost-effectiveness of cascade testing. Read More

    Refinement of variant selection for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replication in samples from 6 countries.
    Clin Chem 2015 Jan 20;61(1):231-8. Epub 2014 Nov 20.
    Centre for Cardiovascular Genetics, British Heart Foundation Laboratories, Institute of Cardiovascular Sciences, and
    Background: Familial hypercholesterolemia (FH) is an autosomal-dominant disorder caused by mutations in 1 of 3 genes. In the 60% of patients who are mutation negative, we have recently shown that the clinical phenotype can be associated with an accumulation of common small-effect LDL cholesterol (LDL-C)-raising alleles by use of a 12-single nucleotide polymorphism (12-SNP) score. The aims of the study were to improve the selection of SNPs and replicate the results in additional samples. Read More

    Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations.
    J Med Genet 2014 Aug 1;51(8):537-44. Epub 2014 Jul 1.
    British Heart Foundation Laboratories, Centre for Cardiovascular Genetics, Institute of Cardiovascular Science, the Rayne Building University College London, London, UK.
    Background: Familial hypercholesterolaemia (FH) is an autosomal dominant disease of lipid metabolism, which leads to early coronary heart disease. Mutations in LDLR, APOB and PCSK9 can be detected in 80% of definite FH (DFH) patients. This study aimed to identify novel FH-causing genetic variants in patients with no detectable mutation. Read More

    The genetic architecture of the familial hyperlipidaemia syndromes: rare mutations and common variants in multiple genes.
    Curr Opin Lipidol 2014 Aug;25(4):274-81
    Centre for Cardiovascular Genetics, Institute of Cardiovascular Science, University College London, London, UK.
    Purpose Of Review: Genome-Wide Association Studies have provided robust identification of approximately 100 genetic loci determining plasma lipid parameters. Using these multiple common genetic lipid-determining variants in a 'gene score' has thrown new light on the mode of inheritance of familial lipid disorders.

    Recent Findings: Different hypertriglyceridaemia states have been explained by the polygenic coinheritance of triglyceride-raising alleles. Read More

    A genetic variant in the LDLR promoter is responsible for part of the LDL-cholesterol variability in primary hypercholesterolemia.
    BMC Med Genomics 2014 Apr 7;7:17. Epub 2014 Apr 7.
    Departamento de Bioquímica y Biología Molecular y Celular, Universidad de Zaragoza, C, Pedro Cerbuna 12, 50009 Zaragoza, Spain.
    Background: GWAS have consistently revealed that LDLR locus variability influences LDL-cholesterol in general population. Severe LDLR mutations are responsible for familial hypercholesterolemia (FH). However, most primary hypercholesterolemias are polygenic diseases. Read More

    What is new in familial hypercholesterolemia?
    Curr Opin Lipidol 2014 Jun;25(3):183-8
    Heart Institute (InCor), University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil.
    Purpose Of Review: The purpose of this review is to describe advances in the diagnosis, cause, metabolism, risk factors for atherosclerosis, and treatment of familial hypercholesterolemia.

    Recent Findings: Heterozygous familial hypercholesterolemia is almost four-fold more frequent than previously thought and is associated with 10-fold to 13-fold risk of cardiovascular disease comparing with normolipidemics. LDL receptor (LDLR) dysfunction and LDL-cholesterol (LDL-C) accumulation disturb the metabolism of other lipoprotein classes, such as chylomicrons and remnants and HDL. Read More

    The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies.
    J Am Coll Cardiol 2014 May 12;63(19):1935-47. Epub 2014 Mar 12.
    Section of Cardiovascular Disease Prevention, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address:
    The severe hypercholesterolemia phenotype includes all patients with marked elevation of low-density lipoprotein cholesterol (LDL-C) levels. The most common cause is autosomal dominant hypercholesterolemia, an inherited disorder caused by mutations either in LDL receptor, apolipoprotein B (APOB), or proprotein convertase subtilisin kexin type 9 (PCSK9) genes. However, it is now known that many subjects with severe inherited hypercholesterolemia have no defects in these genes. Read More

    Cardiovascular risk assessment of dyslipidemic children: analysis of biomarkers to identify monogenic dyslipidemia.
    J Lipid Res 2014 May 13;55(5):947-55. Epub 2014 Mar 13.
    Unidade de Investigação & Desenvolvimento, Grupo de Investigação Cardiovascular, Departamento de Promoção da Saúde e Prevenção de Doenças Não Transmissíveis, Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisboa, Portugal.
    The distinction between a monogenic dyslipidemia and a polygenic/environmental dyslipidemia is important for the cardiovascular risk assessment, counseling, and treatment of these patients. The present work aims to perform the cardiovascular risk assessment of dyslipidemic children to identify useful biomarkers for clinical criteria improvement in clinical settings. Main cardiovascular risk factors were analyzed in a cohort of 237 unrelated children with clinical diagnosis of familial hypercholesterolemia (FH). Read More

    What We Know About Diet, Genes, and Dyslipidemia: Is There Potential for Translation?
    Curr Nutr Rep 2013 Dec;2(4):236-242
    Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
    Cardiovascular disease, particularly coronary artery disease (CAD), is the leading cause of death in the United States. Dyslipidemia, including elevated low density lipoprotein cholesterol (LDL-C) and triglyceride (TG) levels and low high density lipoprotein cholesterol (HDL-C), is a well-established risk factor for CAD and is influenced by both genetic and lifestyle factors, including the diet and dietary fat in particular. Major strides in elucidating the genetic basis for dyslipidemia have been made in recent years, and the quest to clarify how genetic differences influence lipid response to dietary intervention continues. Read More

    Evidence of a polygenic origin of extreme high-density lipoprotein cholesterol levels.
    Arterioscler Thromb Vasc Biol 2013 Jul 16;33(7):1521-8. Epub 2013 May 16.
    Department of Experimental Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.
    Objective: There are several known monogenic causes of high and low high-density lipoprotein cholesterol (HDL-C) levels, but traditional sequencing studies have had limited success in identifying mutations in the majority of individuals with extreme HDL-C levels. The aim of this study was to assess the power of a targeted high-throughput sequencing strategy to elucidate the genetic basis of extreme HDL-C phenotypes.

    Approach And Results: We sequenced 195 genes with either established or implicated roles in lipid and lipoprotein metabolism plus 78 lipid-unrelated genes in patients with HDL-C <1st (n=40) or >99th (n=40) percentile values, and the results were compared with those of 498 individuals representative of the Dutch general population and 95 subjects with normal HDL-C (between 40th and 60th percentile values). Read More

    Radiation risk of individual multifactorial diseases in offspring of the atomic-bomb survivors: a clinical health study.
    J Radiol Prot 2013 Jun 13;33(2):281-93. Epub 2013 Mar 13.
    Department of Clinical Studies, Radiation Effects Research Foundation, Hiroshima and Nagasaki, Japan.
    There is no convincing evidence regarding radiation-induced heritable risks of adult-onset multifactorial diseases in humans, although it is important from the standpoint of protection and management of populations exposed to radiation. The objective of the present study was to examine whether parental exposure to atomic-bomb (A-bomb) radiation led to an increased risk of common polygenic, multifactorial diseases-hypertension, hypercholesterolaemia, diabetes mellitus, angina pectoris, myocardial infarction or stroke-in the first-generation (F1) offspring of A-bomb survivors. A total of 11,951 F1 offspring of survivors in Hiroshima or Nagasaki, conceived after the bombing, underwent health examinations to assess disease prevalence. Read More

    Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study.
    Lancet 2013 Apr 22;381(9874):1293-301. Epub 2013 Feb 22.
    Centre for Cardiovascular Genetics, Institute of Cardiovascular Science, University College London, London, UK.
    Background: Familial hypercholesterolaemia is a common autosomal-dominant disorder caused by mutations in three known genes. DNA-based cascade testing is recommended by UK guidelines to identify affected relatives; however, about 60% of patients are mutation-negative. We assessed the hypothesis that familial hypercholesterolaemia can also be caused by an accumulation of common small-effect LDL-C-raising alleles. Read More

    The TALLYHO mouse as a model of human type 2 diabetes.
    Methods Mol Biol 2012 ;933:75-87
    Department of Pharmacology, Physiology and Toxicology, Marshall University School of Medicine, Huntington, WV, USA.
    The TALLYHO/Jng (TH) mouse is an inbred polygenic model for type 2 diabetes (T2D) with moderate obesity. Both male and female TH mice are characterized by increased body and fat pad weights, hyperleptinemia, hyperinsulinemia, and hyperlipidemia. Glucose intolerance and hyperglycemia are exhibited only in males. Read More

    Heterozygosity for lysosomal acid lipase E8SJM mutation and serum lipid concentrations.
    Nutr Metab Cardiovasc Dis 2013 Aug 12;23(8):732-6. Epub 2012 Jul 12.
    Department of Toxicology, Oncology and Molecular Pathology Unit, University of Cagliari, Italy.
    Background And Aim: The complete absence of the lysosomal acid lipase (LAL) enzyme function causes Wolman's Disease that is fatal within the first six months of life. Subtotal defects cause Cholesteryl ester storage disease (CESD), an autosomal recessive disorder leading to hepatic steatosis, fibrosis, micronodular cirrhosis, combined hyperlipidemia with low HDL-cholesterol, increased risk for atherosclerosis, premature death. Since the frequency of the Exon 8 splice junction mutation (c. Read More

    Cholesterol metabolism differs after statin therapy according to the type of hyperlipemia.
    Life Sci 2012 Jun 24;90(21-22):846-50. Epub 2012 Apr 24.
    Internal Medicine, Angiology and Atherosclerosis, Department of Clinical and Experimental Medicine, University of Perugia, Italy.
    Aim: Non-cholesterol sterols reflect cholesterol metabolism. Statins reduce cholesterol synthesis usually with a rise in cholesterol absorption. Common hyperlipemias have shown different patterns of cholesterol metabolism. Read More

    Transcriptional profiling of human liver identifies sex-biased genes associated with polygenic dyslipidemia and coronary artery disease.
    PLoS One 2011 12;6(8):e23506. Epub 2011 Aug 12.
    Division of Cell and Molecular Biology, Department of Biology, Boston University, Boston, Massachusetts, United States of America.
    Sex-differences in human liver gene expression were characterized on a genome-wide scale using a large liver sample collection, allowing for detection of small expression differences with high statistical power. 1,249 sex-biased genes were identified, 70% showing higher expression in females. Chromosomal bias was apparent, with female-biased genes enriched on chrX and male-biased genes enriched on chrY and chr19, where 11 male-biased zinc-finger KRAB-repressor domain genes are distributed in six clusters. Read More

    Examination of adhesion molecules, homocysteine and hs-CRP in patients with polygenic hypercholesterolemia and isolated hypertriglyceridemia.
    Intern Med 2011 1;50(15):1529-35. Epub 2011 Aug 1.
    Department of Internal Medicine, Division of Endocrinology and Metabolism Izmir, Izmir Dokuz Eylul University, Turkey.
    Background: Increased levels of selectins, adhesion molecules, hs-CRP and homocysteine are considered important as indicators of atherosclerosis. There is a significant amount of evidence that high LDL-C levels are a risk factor for coronary artery disease, whereas the relevance of isolated triglycerides is controversial. The present study aims to compare the levels of homocysteine, hs-CRP, E-selectin, sP-selectin, VCAM-1, ICAM-1 in patients with isolated hypertriglyceridemia and polygenic hypercholesterolemia. Read More

    Genetic and genomic analysis of hyperlipidemia, obesity and diabetes using (C57BL/6J × TALLYHO/JngJ) F2 mice.
    BMC Genomics 2010 Dec 19;11:713. Epub 2010 Dec 19.
    Department of Pharmacology, Physiology and Toxicology, Joan C, Edwards School of Medicine, Marshall University, Huntington, WV 25755, USA.
    Background: Type 2 diabetes (T2D) is the most common form of diabetes in humans and is closely associated with dyslipidemia and obesity that magnifies the mortality and morbidity related to T2D. The genetic contribution to human T2D and related metabolic disorders is evident, and mostly follows polygenic inheritance. The TALLYHO/JngJ (TH) mice are a polygenic model for T2D characterized by obesity, hyperinsulinemia, impaired glucose uptake and tolerance, hyperlipidemia, and hyperglycemia. Read More

    Atorvastatin inhibits oxidative stress via adiponectin-mediated NADPH oxidase down-regulation in hypercholesterolemic patients.
    Atherosclerosis 2010 Nov 19;213(1):225-34. Epub 2010 Aug 19.
    Prima Clinica Medica-University of Rome La Sapienza, Rome, Italy.
    Background: Interventional treatment with atorvastatin lowered the circulating levels of the catalytic core of NADPH oxidase, namely sgp91(phox), but the underlying mechanism is still undefined.

    Aim: To test the hypothesis that the inhibitory effect on oxidative stress, induced by Atorvastatin, could be mediated by adiponectin.

    Methods And Results: We compared 36 patients with polygenic hypercholesterolemia and 18 healthy subjects. Read More

    Non-cholesterol sterols in different forms of primary hyperlipemias.
    Nutr Metab Cardiovasc Dis 2012 Mar 13;22(3):231-6. Epub 2010 Aug 13.
    Internal Medicine, Angiology and Atherosclerosis, Department of Clinical and Experimental Medicine, University of Perugia, Italy.
    Background And Aims: We investigated the behaviour of non-cholesterol sterols, surrogate markers of cholesterol absorption (campesterol and sitosterol) and synthesis (lathosterol), in primary hyperlipemias.

    Methods And Results: We studied 53 patients with polygenic hypercholesterolemia (PH), 38 patients with familial combined hyperlipemia (FCH), and 19 age- and sex-matched healthy control subjects. In all participants, plasma sitosterol, campesterol and lathosterol were determined by gas chromatography coupled to mass spectrometry. Read More

    Telomeres are shorter in myocardial infarction patients compared to healthy subjects: correlation with environmental risk factors.
    J Mol Med (Berl) 2010 Aug 11;88(8):785-94. Epub 2010 Apr 11.
    Centre for Cardiovascular Genetics, BHF Laboratories, the Rayne Building, Department of Medicine, University College London (UCL), 5 University Street, London, WC1E 6JF, UK.
    Shorter telomeres have been reported in premature myocardial infarction (MI) patients. Our work aimed at confirming the association of shorter telomere with MI in two case-control studies and in familial hypercholesterolemia (FH) patients with coronary heart disease (CHD). The HIFMECH study compared 598 white male patients (<60 years) who survived a first MI and 653 age-matched controls from North and South Europe. Read More

    Plasma non-cholesterol sterols: a useful diagnostic tool in pediatric hypercholesterolemia.
    Pediatr Res 2010 Feb;67(2):200-4
    Department of Clinical Medicine and Emerging Diseases, University of Palermo, Palermo I90127, Italy.
    Current guidelines strongly recommend the identification of genetic forms of hypercholesterolemia (HC) during childhood.The usefulness of non-cholesterol sterols (NCS) in the diagnosis of genetic HC has not been fully explored. Plasma NCS were measured by gas chromatography/mass spectrometry (GC/MS) in 113 children with hypercholesterolemia affected by: autosomal dominant hypercholesterolemia (ADH), familial combined hyperlipidemia(FCHL), polygenic hypercholesterolemia (PHC), and in 79 controls to evaluate: i) plasma NCS profile in different genetic HC and ii) the usefulness of NCS for the diagnosis of HC beyond current clinical criteria. Read More

    Ezetimibe as monotherapy in the treatment of hypercholesterolemia in children and adolescents.
    J Pediatr Endocrinol Metab 2009 Jun;22(6):487-92
    Department of Pediatric Endocrinology, University Hospital Vall d'Hebron, Barcelona, Spain.
    Background: A prospective study was conducted to evaluate low-density lipoprotein-cholesterol (LDL-C) lowering efficacy and tolerability of ezetimibe as monotherapy in children and adolescents with polygenic hypercholesterolemia (PH) or familial hypercholesterolemia (FH).

    Methods And Results: Children with PH (n=6) or FH (n=11) aged 5-15 years were consecutively enrolled to receive ezetimibe as monotherapy at 10 mg/day for 11.3 +/- 7. Read More

    Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment.
    J Clin Pharm Ther 2009 Jun;34(3):267-76
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
    Background And Objective: One of the problems associated with reaching the low-density lipoprotein cholesterol (LDL-C) target during statin treatment is the emergence of laboratory or clinical side effects. The aim of our study was to evaluate the prevalence of statin-associated adverse events in diabetic and non-diabetic patients affected by polygenic hypercholesterolemia or combined hyperlipidemia and the efficacy and tolerability of treatment with ezetimibe/simvastatin 10/10 mg/day on the same subjects experiencing the adverse events.

    Methods: Consecutively enrollment of patients affected by polygenic hypercholesterolemia or combined hyperlipidemia with or without type 2 diabetes mellitus. Read More

    [Family and polygenic hypercholesteremia: similarities and differencies according to long-term clinical observations].
    Ter Arkh 2009 ;81(1):61-4
    Aim: Detection and analysis of similarities and differences in patients with family and polygenic hypercholesterolemia (FHCE and PHCE).

    Material And Methods: The study included 100 patients with FHCE and 80 PHCE patients with LD-LP cholesterol level at least 4.3 mmol/l (170 mg/dl). Read More

    Prague hereditary hypercholesterolemic (PHHC) rat - a model of polygenic hypercholesterolemia.
    Physiol Res 2009 ;58 Suppl 2:S95-9
    Center for Cardiovascular Research, Prague, Czech Republic.
    Prague hereditary hypercholesterolemic (PHHC) rat - rat strain crossbred from Wistar rats - is a model of hypercholesterolemia induced by dietary cholesterol. Importantly, no bile salts and/or antithyroid drugs need to be added to the diet together with cholesterol to induce hypercholesterolemia. PHHC rats have only modestly increased cholesterolemia when fed a standard chow and develop hypercholesterolemia exceeding 5 mmol/l on 2 % cholesterol diet. Read More

    Single nucleotide polymorphisms in ABCG5 and ABCG8 genes in Chilean subjects with polygenic hypercholesterolemia and controls.
    Clin Chem Lab Med 2008 ;46(11):1581-5
    Laboratorio de Biología Molecular y Farmacogenética, Departamento de Ciencias Básicas, Facultad de Medicina, Universidad de La Frontera, Temuco, Chile.
    Background: The excretion of cholesterol from liver and intestine is regulated by ATP-binding cassette half-transporters ABCG5 and ABCG8. Polymorphisms in their genes have been related to higher levels of plasma lipids. Thus, the aim of the present study was to evaluate the possible association between the 1950C > G (ABCG5) and the 251A > G (ABCG8) polymorphisms and the presence of hypercholesterolemia (HC) in Chilean subjects. Read More

    Phytosterol-enriched yogurt increases LDL affinity and reduces CD36 expression in polygenic hypercholesterolemia.
    Lipids 2009 Feb 8;44(2):153-60. Epub 2008 Nov 8.
    Department of Internal Medicine, University of Turin, Corso A. M. Dogliotti 14, 10126 Turin, Italy.
    Dietary enrichment with phytosterols (plant sterols similar to cholesterol) is able to reduce plasma cholesterol levels due to reduced intestinal absorption. The aim of this study was to investigate the effect of phytosterol-enriched yogurt consumption on the major serum lipid parameters, low density lipoprotein (LDL) receptor activity, LDL-receptor affinity, and CD36 expression in hypercholesterolemic subjects. Fifteen patients affected by polygenic hypercholesterolemia were evaluated in a single-blind randomized crossover study after a 4 weeks treatment with a phytosterol-enriched yogurt containing 1. Read More

    Differences in expression of cholesterol 7alpha-hydroxylase between PHHC and Wistar rats.
    Folia Biol (Praha) 2008 ;54(1):18-23
    Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
    PHHC rats represent a suitable experimental model of polygenic hypercholesterolemia. It has been found that its metabolic defect is not related to alimentary cholesterol absorption and LDL clearance. We have tested possible changes in cholesterol clearance from the liver to bile acids by analysis of the expression of the cholesterol 7alpha-hydroxylase (cyp7A1) gene in PHHC (N = 20) and Wistar (controls) (N = 19) male rats. Read More

    [Drug of the month. Ezetimibe/simvastatin tablet (Inegy)].
    Rev Med Liege 2007 Sep;62(9):585-90
    Université de Liège, Département de Médecine, CHU Sart Tilman, Liège, Belgique.
    Inegy, recently launched by Merck Sharp & Dohme and Schering Plough, is a fixed combination of simvastatin, which inhibits hepatic cholesterol synthesis, and ezetimibe, which selectively inhibits the intestinal absorption of cholesterol and phytosterols. The two mechanisms of action are complementary and result in a synergistic cholesterol-lowering effect. Three formulations of Inegy are commercialized and reimbursed in Belgium, ezetimibe 10 mg/simvastatin 20 mg, ezetimibe 10 mg/simvastatin 40 mg and ezetimibe 10 mg/ simvastatin 80 mg. Read More

    The relationship between dose of vitamin E and suppression of oxidative stress in humans.
    Free Radic Biol Med 2007 Nov 4;43(10):1388-93. Epub 2007 Jul 4.
    Department of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA.
    The oxidation hypothesis of atherogenesis has been the focus of much research over the past 2 decades. However, randomized placebo-controlled trials evaluating the efficacy of vitamin E in preventing cardiovascular events in aggregate have failed to show a beneficial effect. Implicit in these trials is that the dose of vitamin E tested effectively suppressed oxidative stress status but this was never determined. Read More

    1 OF 4